Ultrasis Share Discussion Threads

[wulwirth] 01/7/2018 21:19

Spent 500 on supplements, just got a contact with thc in cbd, GP appears not to help either, illegal hemp license only. She takes a very high dose of powder vit C.

[humphries1] 29/6/2018 14:51

wooly some laws are so stupid its unreal one of the worst is were women have to wear cloths with only slits for eyes what about the vitamin b or d sorry cant remember which the body gets from sunlight

[wulwirth] 28/6/2018 19:06

Ok humph, from the Hemp Plant CBD oil is legal TCH is illegal, in Canada they use both CBD/TCH for medical treatment, been legal since 2001.

Recreational cannabis has been legalise and available to buy form September 2018.

We share the same Queen with different laws lol...

[humphries1] 23/6/2018 08:30

hi wooly yes its opened my eyes about cannabis oil, i will take a look

[wulwirth] 21/6/2018 22:22

humph its a must look into medical cannabis, CBD oil from reliable source :)

Example* The Health Shop Mansfield Woodhouse very expensive, but if it works, well worth the dosh, especially compared to the amount this bad company took from us.


Good Luck.

[humphries1] 06/6/2018 07:45

cheers wooly best of luck monday, i have my prostate scan today, hope i dont have to have the operation again

[wulwirth] 05/6/2018 22:58

Cheers humph message you next week after Monday visit, good luck with opti and the others :)

[humphries1] 01/6/2018 07:42

hi wooly sorry to hear that its health hope it turns out the results are good and not bad.
yes wooly OPTI looks like its going to be big, first time i have said that and certain it will be

[wulwirth] 31/5/2018 22:45

Yes humph health issue, when get more info will direct mail you, this is why Ive not been posting. Be nice to read someone made some dosh, rather than aim rip offs :)

[humphries1] 31/5/2018 07:17

hi wooly more news from OPTI, SWEETBIOTIX is what i want to get shares in when it floats
31 May 2018

OptiBiotix Health plc

("OptiBiotix" or the Company")

SweetBiotix(R): Evaluation agreement with global dairy company

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high

cholesterol and diabetes, announces that it has entered into an evaluation agreement with a global dairy company for its SweetBiotix(R) calorie free sweet fibres. The agreement grants a non-exclusive license for an evaluation period to explore the potential for using the SweetBiotix(R) technology to reduce the sugar content in a range of its dairy food products.

OptiBiotix has previously announced (RNS: 27 March 2018) that the five successful human taste studies on the SweetBiotix(R) product development had created interest from a number of corporates with expertise in the manufacture and commercialisation of speciality ingredients and/or consumer products. This agreement reflects interest from one of these companies in exploring the use of SweetBiotix(R) in its branded dairy products.

The company is a global brand and one of the world's largest providers of dairy products with an annual turnover exceeding $10bn. The details of the evaluation and terms of the agreement are confidential and no further details can be disclosed. A further announcement will be made in due course.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of this agreement for SweetBiotix(R) with one of the world's largest dairy companies and such a well-known global brand. This is part of a strategy of working with global partners who have the capability and expertise to manufacture speciality ingredients like SweetBiotix(R) and well-known consumer brands who have the specialist application expertise to incorporate this technology into their own branded breaded, dairy, cereal and beverage consumer products. This approach provides a low risk way to fully exploit the wide range of opportunities offered by our SweetBiotix(R) technology."

[humphries1] 31/5/2018 06:55

sorry wooly do you mean health results, i am waiting for scan on my prostate again, i had one operation a few years back, not nice.
also floaters in my eyes which can stop me driving if they get bad enough its like looking through cobwebs with 2 or 3 tadpoles in amongst them

[wulwirth] 30/5/2018 13:19

Still here humph waiting for some results, long winded grrr

[humphries1] 25/5/2018 08:32

cheers wooly

[wulwirth] 24/5/2018 23:09

Maybe get back next week, but direct humph, good luck.

[humphries1] 22/5/2018 07:14

hi wooly hope the problems gets sorted and no with lasting affects

[wulwirth] 21/5/2018 16:35

Hi humph, having a few problems, will email you direct when more clear, good luck with it :)

[humphries1] 18/5/2018 15:07

yes wooly there is a hell of a lot going on at OPTI a lot we dont know about yet, there is nothing wrong with taking a profit, a mate of mine got into bitcoin i told him keep taking money of the table as its going up then hold that cash till there is a big drop then hit them again, so long as there is nothing very wrong with it.
one thing investors like wooly is figures but OPTI wont let any thing out the bag to upset companies that they are doing deals with, the only time we will get them is in the results but no company will have any idea from them at whats going on, if you see what i mean i am not very good at putting things on paper, so lets just wait for results and see what happens

[wulwirth] 18/5/2018 10:42

Don't think I've noticed another company with such regular updates, strange that the shareprice stutters.

IMO investors are taking profit, something a lot seem shy of.

[humphries1] 18/5/2018 08:13

hi wooly another little read on OPTI
18 May 2018

OptiBiotix Health plc
("OptiBiotix" or the "Company")

SlimBiome® wins award at Vitafoods 2018

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, and diabetes announces that it has won the award for Weight Management Ingredient of the Year at the Vitafoods European tradeshow in Geneva. The award is given to the product identified by a panel of scientific, regulatory and industry experts demonstrating leading edge research and innovation in the weight management market.

SlimBiome® is a next generation patented weight management ingredient developed by world leading key opinion leaders in nutrition and satiation to help manage weight loss by reducing hunger. This leads to less snacking and easier weight loss. It is heat stable, easy to process and has been incorporated into bread, biscuits, dairy, gummies, muesli pots, healthy snacks & bars, and a range of cereals in puff, flakes, and crisp format.

Independent human studies by Oxford Brookes University have demonstrated that if you compare control and test groups who take SlimBiome® or a placebo, the SlimBiome® group: -

· Feel fuller and are less hungry
· Have less food cravings
· Change their food choice so eat less sweet or fatty foods

This contrasts with current products on the market which often lack strong scientific evidence or clinical studies and typically rely on customers' self-control to restrict calories and as a consequence have a high failure rate. Independent consumer studies have shown that 100% of customers who used SlimBiome® in OptiBiotix's GoFigure® products lost weight, on average 2-3lbs per week. Most importantly these customers found the products relieve hunger pangs leading to easier dieting.

The award for Weight Management Ingredient of the Year at Vitafoods is the second industry award for SlimBiome®, following on from winning the award for 'Best Functional Ingredient for Health and Well Being' at Food Matters in November 2017.

SlimBiome® is the first in a range of products being developed by OptiBiotix which help to improve human health through the science of the microbiome. Other products under development in the range include ImmunoBiome, ® CardioBiome® and WellBiome®.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to receive this award which provides independent industry recognition of the innovation and scientific credibility behind the development of SlimBiome® and it's potential to help manage weight gain and improve consumers health and wellbeing. Having a product with a known mechanism of action, clinical and consumer studies showing its safety and effectiveness, and the support of leading international key opinion leaders, helps give confidence to consumers in their product choice. Hunger free dieting is now a consumer option and we hope that the increasing number of food applications containing SlimBiome® will help bring the benefits of this exciting new technology to a wider international audience."

[humphries1] 17/5/2018 13:53

hi wooly as i think OPTI will do for health what the mobile phone did for communications, thats just my thinking wooly , and also thinking big dividends in the years to come

[wulwirth] 17/5/2018 11:18

Looking good humph :)

[humphries1] 16/5/2018 07:21

hi wooly another little read for you from OPTI
16 May 2018

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Exclusive manufacturing and supply agreement

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into a five year agreement with Akums Drugs and Pharmaceuticals Ltd ("Akums") to exclusively manufacture and supply products containing OptiBiotix's cholesterol and blood pressure reducing strain LP(LDL) (R) , in India.

The agreement is a strategic step with the leading contract manufacturer in India to extend the opportunities offered by LP(LDL) (R) into India and Southern Asia.

Under the terms of the agreement, Akums will manufacture and supply products containing OptiBiotix's LP(LDL) (R) throughout India to maximise the financial return for both parties. In return for exclusivity, Akums will provide undisclosed and in-kind contributions and will explore the opportunities to utilise LP(LDL) (R) with OptiBiotix for biotherapeutics in India, including the authority registrations that would be required. Akums will contribute to human studies if required for product marketing purposes or by the Food Safety Standards Authority of India ("FSSAI") as part of product registration into food. The agreement does not have any minimum sales orders and the Company will update the market on sales in due course.

Akums is the largest contract manufacturing organisation in India, a manufacturing partner of choice to more than 600 companies, such as Abbott, Novartis, P&G, Sanofi and Sandoz, in the pharmaceutical and food supplement space. The company has 11 world class, WHO-GMP certified manufacturing facilities with US-NSF, NABL, FSSAI, HACCP and other accreditations, which cater for all major dosage forms (e.g tablets, capsules, syrups, suspensions, sterile parenterals, creams-ointments etc.). The company offers more than 3,500 supplement and pharmaceutical formulations across key health areas such as cardiovascular disease. Akums offers significant manufacturing capacity and supplies more than 12% of all food and drug supplements consumed in India.

India has a population of 1.3 billion people with cardiovascular disease accounting for up to 26% of all deaths, and 21% of the population suffering from hypertension (WHO). 80% of the population have abnormal lipid levels with 72% having low levels of 'HDL' or 'good cholesterol' (The Times of India June 8, 2014). Products containing LP(LDL) (R) have a unique ability to increase 'HDL' and reduce both bad cholesterol (LDL) and blood pressure, providing a clinically proven natural product to help reduce cardiovascular risk factors in countries with a high prevalence of these conditions.

Stephen O'Hara, CEO of OptiBiotix, commented: "We are excited to announce this agreement with Akums which expands manufacturing and sales of LP(LDL) (R) into Asia. We chose Akums as they are the largest contract manufacturing company in India for both food supplements and pharmaceuticals and have extensive experience in manufacturing products for some of the biggest food and pharmaceutical companies in the world. This agreement is a strategic step to add manufacturing to the supply chain in the Asian probiotic supplement and pharmaceutical market and extends the commercial reach of OptiBiotix's LP(LDL) (R) strain into Southern Asia. This allows OptiBiotix to offer multiple product solutions to consumer health and pharmaceutical companies within the region. This agreement is another step in a strategy designed to build multiple revenue streams from ingredient sales, white label and own label branded consumer and pharmaceutical products, across multiple channels, with leading industry partners from around the world."

[humphries1] 14/5/2018 16:06

hi wooly not really been into skin share price i am waiting for the SWEETBIOTIX i want shares in that when it floats

[wulwirth] 14/5/2018 15:35

De-risk sounds better than bells de-list, skin trading above float price aren't they, skin slightly down.